This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Troke, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Troke, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1743-1750, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01388-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients{triangledown}

Peter Troke,1* Koldo Aguirrebengoa,2 Carmen Arteaga,3 David Ellis,4 Christopher H. Heath,5 Irja Lutsar,6 Montserrat Rovira,7 Quoc Nguyen,8 Monica Slavin,9 Sharon C. A. Chen,10 on behalf of the Global Scedosporium Study Group

The Old Court, Broadstairs, Kent, United Kingdom,1 Hospital de Cruces, Baracaldo Vizcaya, Spain,2 Pfizer Inc., New York, New York,3 Women's and Children's Hospital, Adelaide, Australia,4 Royal Perth Hospital, Perth, Australia,5 University of Tartu, Tartu, Estonia,6 Hematology Hospital Clinic, Barcelona, Spain,7 St. Vincent's Hospital, Sydney, Australia,8 Peter MacCallum Cancer Centre, Melbourne, Australia,9 Westmead Hospital, Sydney, Australia,10

Received 26 October 2007/ Returned for modification 29 December 2007/ Accepted 10 January 2008

The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% of patients had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), and surgery/trauma (15%) were the predominant underlying conditions. A successful therapeutic response was achieved in 57% of patients (median, 103 therapy days), with >98% of those responding receiving ≥28 days of therapy. Patients receiving primary therapy showed a 61% response versus 56% for the others. The best therapeutic responses were seen for skin/subcutaneous (91%) or bone (79%) infections, and the lowest for CNS infections (43%). Patients without major immune suppression (72%) or those with solid organ transplantation (63%) or various hematological conditions (60%) showed the best responses by underlying condition. Median known survival time was 133 days (therapy successes, 252 days; failures, 21 days). In all, 43 (40%) patients died, 73% due to scedosporiosis. Patients with Scedosporium prolificans infection had significantly reduced survival times (P = 0.0259) and were more likely to die from fungal infection (P = 0.002) than were Scedosporium apiospermum-infected patients. In a subset of 43 patients where voriconazole baseline MICs were available, response to voriconazole was higher for S. apiospermum-infected patients (54% response; MIC50, 0.25 µg/ml) than for S. prolificans-infected patients (40% response; MIC50, 4.0 µg/ml). Voriconazole demonstrated clinically useful activity in the treatment of both S. apiospermum and S. prolificans infections and was well tolerated.

* Corresponding author. Mailing address: The Old Court (c/o Peter Troke), 74a Kingsgate Avenue, Broadstairs, Kent CT10 3LW, United Kingdom. Phone and fax: 44-1843-863900. E-mail: peter2troke{at}btinternet.com

{triangledown} Published ahead of print on 22 January 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1743-1750, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01388-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M. M., Calvo, E., Serena, C., Marine, M., Pastor, F. J., Guarro, J. (2009). Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans. Antimicrob. Agents Chemother. 53: 2153-2155 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»